These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 11993695)

  • 1. Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker.
    Jialal I; Devaraj S
    Am J Clin Pathol; 2001 Dec; 116 Suppl():S108-15. PubMed ID: 11993695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
    Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
    J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
    Sellmayer A; Limmert T; Hoffmann U
    Int Angiol; 2003 Mar; 22(1):15-23. PubMed ID: 12771851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inflammation, C-reactive protein, and atherothrombosis.
    Ridker PM; Silvertown JD
    J Periodontol; 2008 Aug; 79(8 Suppl):1544-51. PubMed ID: 18673009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events.
    Vainas T; Stassen FR; de Graaf R; Twiss EL; Herngreen SB; Welten RJ; van den Akker LH; van Dieijen-Visser MP; Bruggeman CA; Kitslaar PJ
    J Vasc Surg; 2005 Aug; 42(2):243-51. PubMed ID: 16102622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice.
    Ridker PM
    Am Heart Hosp J; 2004; 2(4 Suppl 1):4-9. PubMed ID: 15539969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between cardiovascular disease risk factors and IL-6 and hsCRP levels in the elderly.
    Nadrowski P; Chudek J; Skrzypek M; Puzianowska-Kuźnicka M; Mossakowska M; Więcek A; Zdrojewski T; Grodzicki T; Kozakiewicz K
    Exp Gerontol; 2016 Dec; 85():112-117. PubMed ID: 27729238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk stratification and prognostic implication of plasma biomarkers in nondiabetic patients with stable coronary artery disease: the role of high-sensitivity C-reactive protein.
    Leu HB; Lin CP; Lin WT; Wu TC; Chen JW
    Chest; 2004 Oct; 126(4):1032-9. PubMed ID: 15486359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of lipid and inflammatory markers with C-reactive protein in cardiovascular risk assessment for primary prevention.
    Jovicić S; Ignjatović S; Dajak M; Kangrga R; Majkić-Singh N
    Clin Lab; 2009; 55(11-12):411-9. PubMed ID: 20225663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preventive cardiology: move over low density lipoprotein cholesterol, hello C-reactive protein?
    Genest J
    Can J Cardiol; 2004 Aug; 20 Suppl B():89B-92B. PubMed ID: 15309211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus.
    Pfützner A; Forst T
    Diabetes Technol Ther; 2006 Feb; 8(1):28-36. PubMed ID: 16472048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relations of plasma high-sensitivity C-reactive protein to traditional cardiovascular risk factors.
    Saito M; Ishimitsu T; Minami J; Ono H; Ohrui M; Matsuoka H
    Atherosclerosis; 2003 Mar; 167(1):73-9. PubMed ID: 12618270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel role of C-reactive protein in cardiovascular disease: risk marker or pathogen.
    Wilson AM; Ryan MC; Boyle AJ
    Int J Cardiol; 2006 Jan; 106(3):291-7. PubMed ID: 16337036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?
    Ridker PM; Wilson PW; Grundy SM
    Circulation; 2004 Jun; 109(23):2818-25. PubMed ID: 15197153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory bio-markers and cardiovascular risk prediction.
    Blake GJ; Ridker PM
    J Intern Med; 2002 Oct; 252(4):283-94. PubMed ID: 12366601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.
    Ridker PM
    J Am Coll Cardiol; 2007 May; 49(21):2129-38. PubMed ID: 17531663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-sensitivity C-reactive protein: clinical importance.
    Bassuk SS; Rifai N; Ridker PM
    Curr Probl Cardiol; 2004 Aug; 29(8):439-93. PubMed ID: 15258556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors.
    Olsen MH; Christensen MK; Hansen TW; Gustafsson F; Rasmussen S; Wachtell K; Borch-Johnsen K; Ibsen H; Jørgensen T; Hildebrandt P
    J Hypertens; 2006 Apr; 24(4):655-61. PubMed ID: 16531793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-reactive protein: a nontraditional serum marker of cardiovascular risk.
    de Ferranti SD; Rifai N
    Cardiovasc Pathol; 2007; 16(1):14-21. PubMed ID: 17218210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany.
    Koenig W; Khuseyinova N; Löwel H; Trischler G; Meisinger C
    Circulation; 2004 Oct; 110(14):1903-8. PubMed ID: 15451783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.